Abstract 1210
Background
Several studies suggested the prognostic importance of sarcopenia and anemia in survival or treatment complications in cancer. The aim of our study was to identify prognosis factors on chemotherapy toxicities and survival in patients (pts) with localized muscle invasive bladder cancer (MIBC).
Methods
Between January 2012 and December 2017, pts who underwent neoadjuvant platinum-based chemotherapy (NAC) followed by radical cystectomy (RC) for cT2-T4 N0 M0 MIBC were retrospectively selected, from a single institution cohort. Sarcopenia was evaluated according to the Lumbar Skeletal Muscle Index (SMI) in L3 using CT scan before NAC, after NAC and after RC. Pretreatment anemia was defined as hemoglobin rate < 13g/dL for men and < 12g/dL for women, prior to treatment.
Results
Of 82 pts selected, 62 are men (75.6%) and 20 women (24.4%), with a median age of 64.5 years (31 to 80). Median SMI was 47.5cm2/m2 for men and 36.6 cm2/m2 for women. Pretreatment sarcopenia was significantly associated with nausea (p = 0.003), hypokalemia (p = 0.023) and with platinum dose-intensity during NAC (p = 0.007). 46 out of 74 pts had a SMI decrease greater than 5% during chemotherapy, that was associated with poor OS (HR = 4.8, CI95% [1.42-16.4], p = 0.003). Pretreatment anemia was significantly associated with OS (HR = 2.86, CI95% [1.21-6.76], p = 0.026). Transfusion during chemotherapy was not associated with survival. In multivariate analysis, factors associated with OS were SMI loss > 5% (HR = 4.62, CI95% [1,25-11,9]), positive pN status (HR = 7.66, CI95% [2,53-23,1]), histological complete response (HR = 0.22, CI95% [0,053-0,88]), pretreatment anemia (HR = 7.34, CI95% [2,26-23,8]) and ECOG status ≥ 1 (HR = 4.1, CI95% [1,41-11,9]).
Conclusions
For localized MIBC, sarcopenic status before NAC could predict some chemotherapy toxicities whereas pretreatment anemia could be associated with poor OS. Loss in SMI during chemotherapy is an independent prognostic factor for OS. Improve pts care by prehabilitation during NAC and before surgery, using physical, nutritional and psycho-social supports, could decrease chemotherapy toxicities and improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Paoli-Calmettes.
Funding
Has not received any funding.
Disclosure
J. Walz: Research grant / Funding (self): Exact Imaging; Honoraria (self), Speaker Bureau / Expert testimony: Janssen; Honoraria (self), Speaker Bureau / Expert testimony: Takeda; Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Blue Earth Diagnostics; Travel / Accommodation / Expenses: Ipsen. S. Dermeche: Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: AstraZeneca. C. Vicier: Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Pfizer. G. Pignot: Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Astellas; Advisory / Consultancy: BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: Bouchara; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract